Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Agrippal

- PMLiVE

Greece steps up Novartis corruption probe after suicide attempt

Accelerates investigation into whether Novartis paid bribes to doctors and civil servants to drive sales

- PMLiVE

Sanofi and Merck & Co finalise vaccine alliance split

Dissolve Sanofi Pasteur MSD after poor sales growth

Novartis day

Novartis buys two firms in pre-Christmas shopping spree

Acquires eye disease specialist Encore Vision and NASH drug firm Conatus Pharma

Deal Watch November 2016

Actelion, Allergan, Johnson & Johnson, Novartis and more feature in this month's pharma deals round-up

Novartis building

Novartis adds oral eczema drug with Ziarco acquisition

Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect

- PMLiVE

Making a list and checking it twice…

The promise of mobile health lies not in recording information but in promoting behaviour change

- PMLiVE

Novartis’ AMD drug pegpleranib fails phase III programme

Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit

- PMLiVE

Pfizer’s SMO inhibitor boosts survival in blood cancer trial

Glasdegib first to show benefit in patients with AML or MDS

- PMLiVE

Novartis plans filing for lead CAR-T therapy early next year

Shows complete remission for 82 percent of paediatric and young adult B-cell ALL patients

UK pharma continues to approach social media cautiously

Novartis UK becomes the latest in a trickle of firms to join Twitter

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

- PMLiVE

Novartis buys blood disease specialist Selexys

$665m deal prompted by positive phase II data for sickle cell disease therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links